Loading
MB
Marrone Bio Innovations Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by VAN HERK INVESTMENTS B.V., was filed 25 Feb 2019.
Marrone Bio Innovations Inc: what insiders have been doing
Marrone Bio Innovations Inc belongs to the Food & Beverage sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Marrone Bio Innovations Inc in twelve months, the latest record being from 15 July 2022.
Looking back to 2016, when coverage begins, insiders filed 27 purchases and 20 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
165
Thresholds
n/a
Buy Volume
€25M
27 ops. · all time
Sell Volume
€4M
20 ops. · all time
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$38.2M
Gross profitUS$23.5M61% margin
Net income-US$14.3M-37.4% margin
Last declaration on 15 July 2022
Declarations165 total
285,892 sharesCommon StockSEC:0001209191-22-042223:1
212,374 sharesCommon StockSEC:0001209191-22-042222:1
102,167 shares0Common StockSEC:0001209191-22-042222:0
70,836,258 sharesCommon Stock, $0.00001 par valueSEC:0001213900-22-039487:0
129,184 shares0Common StockSEC:0001209191-22-042223:0
2,394,141 sharesCommon StockSEC:0001209191-22-042206:1
6,442 sharesCommon StockSEC:0001209191-22-042206:2
167,812 sharesCommon StockSEC:0001209191-22-042203:1
468,527 sharesCommon StockSEC:0001209191-22-042204:1
429,881 sharesCommon StockSEC:0001209191-22-042201:1
5,000 sharesCommon StockSEC:0001209191-22-042201:2
4,684 sharesCommon StockSEC:0001209191-22-042209:1
273,643 sharesCommon StockSEC:0001209191-22-042200:1
321,770 sharesCommon StockSEC:0001209191-22-042202:1
221,437 sharesCommon StockSEC:0001209191-22-042212:1
450,839 sharesCommon StockSEC:0001209191-22-042210:1
276,479 sharesCommon StockSEC:0001209191-22-042205:1
273,643 shares0Common StockSEC:0001209191-22-042200:0
276,479 sharesCommon StockSEC:0001209191-22-042205:0
195,007 sharesCommon StockSEC:0001209191-22-042206:0
102,950 shares0Common StockSEC:0001209191-22-042212:0
4,850,521 sharesCommon StockSEC:0001209191-22-042209:0
455,027 shares0Common StockSEC:0001209191-22-042204:0
321,770 shares0Common StockSEC:0001209191-22-042202:0
429,081 shares0Common StockSEC:0001209191-22-042201:0
25 of 165 declarations
About Marrone Bio Innovations Inc
Marrone Bio Innovations Inc. (MBII) was a United States-based agricultural biosolutions company focused on biological products for crop protection and plant health. The company was rooted in Davis, California, which fits its innovation profile in agronomy and applied microbiology. For investors in France, Belgium, and Switzerland, it is important to note that MBII was a U.S.-listed company on the NASDAQ market, operating under the SEC disclosure framework and subject to U.S. insider-transaction reporting through Form 4 filings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001748858/000120919121000351/xslF345X03/doc4.xml?utm_source=openai))
MBII’s core business centered on discovering, developing, and commercializing biological solutions intended to improve crop performance while reducing reliance on conventional chemical inputs. Its portfolio included biofungicides, bioinsecticides, bioherbicides, biostimulants, and seed-treatment solutions. This placed the company in a niche but strategically important segment of agriculture: biological crop inputs. Competitive differentiation in this category typically depends on product efficacy, regulatory acceptance, field performance, and the ability to fit into integrated pest-management programs. MBII’s positioning therefore reflected a science-led business model, competing against both large agrochemical groups and a growing set of specialized bioscience players. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001748858/000120919121000351/xslF345X03/doc4.xml?utm_source=openai))
Read moreShow less
Geographically, the company was primarily centered in the United States, but its commercial logic was inherently international because biological crop inputs can scale across major farming regions through distributors and strategic partnerships. MBII was not a fully integrated global crop-input giant; rather, it was a smaller, innovation-driven ag-biotech company with meaningful dependence on commercialization execution, market adoption cycles, and capital-market support. That profile often makes such companies more volatile than mature agricultural majors, but also more exposed to upside if biological products gain traction with growers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001748858/000120919121000351/xslF345X03/doc4.xml?utm_source=openai))
A key recent milestone was the company’s change-of-control transaction in 2022, in which it was folded into Bioceres Crop Solutions. That event materially changed MBII’s standalone market profile and means that recent SEC materials, including Form 4 insider filings and merger-related disclosures, are especially relevant for understanding the company’s legacy equity story. In practical terms, MBII should be viewed as a former U.S. NASDAQ-listed biological agriculture innovator, headquartered in California, whose history illustrates the consolidation trend in agri-biotech and biosolutions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1441693/000120919122042206/xslF345X03/doc4.xml?utm_source=openai))
